ID   GFP-CD16-V/V.NK-92
AC   CVCL_W734
DR   Wikidata; Q54835740
RX   Patent=US9181322;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8836.
CC   Population: Caucasian.
CC   Genetic integration: Method=Transduction; Gene=FPbase; 1XF1B; GFP (Note=avGFP; original A.victoria green fluorescent protein).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:3619; FCGR3A (Note=With p.Phe176Val).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Natural killer cell; CL=CL_0000623.
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2142 ! NK-92
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 10-04-25; Version: 16
//
RX   Patent=US9181322;
RA   Campbell, Kerry S.
RT   "Genetically modified human natural killer cell lines.";
RL   Patent number US9181322, 10-Nov-2015.
//